Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2026 09:07 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and...
March 11, 2026 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being...
March 11, 2026 04:30 ET | Source: Commit Biologics

Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic

Commit Biologics appoints seasoned biotech entrepreneur Thomas L. F. Montgomery Andresen, PhD, as Chief Executive Officer.
March 10, 2026 22:59 ET | Source: Society For Science

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

Regeneron and Society for Science announced that Connor Hill, 17, of State College, PA, won the top $250,000 award in the Regeneron Science Talent Search
March 10, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients
March 10, 2026 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 10, 2026 04:30 ET | Source: Kainova Therapeutics

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.
March 09, 2026 09:15 ET | Source: Esaote

Esaote launches the new MyLab™ E85 GTS ultrasound system in Vienna

Esaote unveils MyLab E85 GTS ultrasound in Vienna, combining fusion imaging and ablation confirmation to boost precision in interventional radiology today.
March 06, 2026 16:10 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
March 06, 2026 10:07 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS...